DFCI-002-05

N/A

Report date: 2025/06/11 11:07:36
NME

Base Information

Drug NameDFCI-002-05
Drug Alias NameDFCI-002-06
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsAnticancer protein kinase inhibitorsTyrosine-protein kinase HCK inhibitors
TargetsTyrosine-protein kinase BTKTyrosine-protein kinase HCK
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer Institute
Inactive CompaniesN/A
Active IndicationsWaldenstrom MacroglobulinemiaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A